Cancer care cost-effectiveness in low-income and middle-income countries: time to shift the burden of proof
Lancet Glob Health
.
2022 Aug;10(8):e1084-e1085.
doi: 10.1016/S2214-109X(22)00289-3.
Author
Matthew S Painschab
1
Affiliation
1
UNC Project Malawi, Private Bag A-104, Lilongwe, Malawi; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: painschabm@med.unc.edu.
PMID:
35839803
DOI:
10.1016/S2214-109X(22)00289-3
No abstract available
Publication types
Research Support, N.I.H., Extramural
Comment
MeSH terms
Cost-Benefit Analysis
Developing Countries*
Humans
Income
Neoplasms* / therapy
Poverty
Grants and funding
K01 TW011470/TW/FIC NIH HHS/United States
L30 CA233709/CA/NCI NIH HHS/United States
L30 TW011802/TW/FIC NIH HHS/United States